Assignee

Peloton Therapeutics, Inc.

Patents = 17

Forward Citations = 113

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

52 inventors (with patents filed for the assignee):

Peloton Therapeutics is a biopharmaceutical company dedicated to developing targeted small molecule drugs to treat cancer and other life-threatening diseases. Our lead drug candidate, PT2977, is an oral HIF-2 inhibitor currently being evaluated for the treatment of clear cell renal cell carcinoma (ccRCC) and other solid tumors. We are committed to advancing science and transforming patients' lives through innovative therapies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com